Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc.


3 Preston Court Bedford MA 01730

Type of Company



Holding Companies

Company Description

Stoke Therapeutics, Inc. engages in the research and development of treatments for genetic diseases. It is a biotechnology firm that focuses to increase gene expression to treat severe genetic diseases, including genetic conditions affecting the central nervous system, eye, ear, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in 2018 is headquartered in Bedford, MA.

Executives & Employees



Chief Executive Officer & Director

Chief Financial Officer

Chief Operating Officer & Chief Business Officer

Chief Medical Officer

Vice President, Head of Chemistry

Executive Vice President & Head of Research & Preclinical Development

Vice President, Head of Clinical Operations

Senior Vice President of Regulatory Affairs & Quality

Board of Directors

Co-Founder at Stoke Therapeutics, Inc.

Partner at Apple Tree Partners

Site Controller-Meeth at Lenox Hill Hospital

Diplomat at American Board of Toxicology

President & Chief Executive Officer at Homology Medicines, Inc.

Paths to Stoke Therapeutics, Inc.
Potential Connections via
Relationship Science
Stoke Therapeutics, Inc.
Recent Transactions
Details Hidden

Stoke Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Cormorant invests in companies primarily located in North America. The firm targets companies in sectors such as life-science and biotech. It provides equity financing for later stage capital requirements.

Details Hidden

Alexandria Venture Investments LLC invests in companies located in the US. The firm targets companies operating in the fields of medical, health andlife sciences sector. They provides financing for seed, early and growth stage capital requirements.

Details Hidden

SFML is a hands-on manager which aims to maximize returns and preserve capital for clients by primarily investing in listed Israeli companies to create a well-balanced, long-term portfolio.The firm takes a conservative approach to market exposure and leverage, managing risk by implementing a disciplined trading approach, using stop-losses and defined price targets for individual positions. They seek to reduce market risk by using correlated derivatives, shorting market indices, sector ETFs, or specific industry stocks with similar drivers and aim to neutralize currency risk by hedging all non-dollar denominated investments in their portfolio.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Stoke Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Stoke Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Stoke Therapeutics, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15